NEW YORK, April 4, 2019 /PRNewswire/ — Phreesia, the top-ranked patient intake management platform, according to the research firm KLAS, is pleased to announce that it is now listed and available on Epic’s App Orchard. Through the App Orchard program, Phreesia offers Epic clients an intake solution that is individualized, easy-to-implement and cost-effective.
“Joining the App Orchard marketplace allows us to accelerate our mission of giving every patient a unique, meaningful intake experience,” said Phreesia CEO Chaim Indig.
Phreesia’s automated platform is designed to transform the patient and provider experience, engaging patients in their care and reducing administrative waste.
Features include:
“We’re very excited to bring Phreesia to the Epic App Orchard marketplace, where we’re able to not only meet the needs of the health system community but to transform the healthcare experience,” said Phreesia’s Senior Vice President of Marketing and Business Development Michael Davidoff.
About Phreesia
Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing and enhance clinical care.
Epic is a registered trademark of Epic Systems Corporation.
View original content to download multimedia:http://www.prnewswire.com/news-releases/phreesia-joins-the-epic-app-orchard-marketplace-300824849.html
SOURCE Phreesia
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…